Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $568.40 Consensus Target Price from Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have been assigned an average rating of “Hold” from the eleven analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $568.40.

QNCX has been the topic of a number of analyst reports. Cantor Fitzgerald began coverage on Quince Therapeutics in a research report on Tuesday, June 23rd. They set an “overweight” rating and a $80.00 target price on the stock. Leerink Partners initiated coverage on Quince Therapeutics in a research note on Wednesday, June 24th. They set an “outperform” rating and a $80.00 price objective for the company. Oppenheimer initiated coverage on Quince Therapeutics in a report on Wednesday, July 29th. They set an “outperform” rating and a $82.00 price objective on the stock. Zacks Research raised Quince Therapeutics to a “hold” rating in a research report on Wednesday, June 24th. Finally, Wall Street Zen upgraded Quince Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in shares of Quince Therapeutics in the 2nd quarter worth about $37,000. Intellectus Partners LLC bought a new position in shares of Quince Therapeutics during the fourth quarter worth about $179,000. Bridgeway Capital Management LLC grew its stake in Quince Therapeutics by 20.9% in the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after purchasing an additional 22,200 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in Quince Therapeutics in the fourth quarter worth about $213,000. Finally, Quadrature Capital Ltd bought a new stake in Quince Therapeutics in the fourth quarter valued at about $268,000. 30.75% of the stock is currently owned by institutional investors.

Quince Therapeutics Trading Up 2.3%

Shares of QNCX stock opened at $29.54 on Friday. The firm has a fifty day simple moving average of $19.76 and a 200-day simple moving average of $59.89. The company has a market capitalization of $30.04 million, a PE ratio of -0.14 and a beta of 1.36. Quince Therapeutics has a twelve month low of $15.10 and a twelve month high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($26.00) by $25.41. Equities research analysts predict that Quince Therapeutics will post -2.72 EPS for the current year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.